 DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 GLOBE NEWSWIRE -- Iterum Therapeutics plc Nasdaq: ITRM the Company, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced today that it will effect a 1-for-15 reverse share split of its outstanding ordinary shares at 5.00 p.m. Eastern Time on August 17, 2022, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on August 18, 2022. 